AEON Biopharma Inc. Overview

AEON Biopharma, Inc., a clinical-stage biopharmaceutical company based in Irvine, United States, specializes in discovering therapeutic neurotoxins and other medications to address various neurological conditions. The company serves its customers in the United States and trades on the New York Stock Exchange American. As of June 15, 2025, AEON Biopharma’s stock closed at $0.851, with a market capitalization of $10,080,000 USD. The company’s 52-week high was $269.28 on July 14, 2024, and its 52-week low was $0.375 on April 10, 2025. The price-to-earnings ratio stands at 0.00299.

AEON’s Involvement in Crypto Payments

Recent developments have seen AEON, a next-generation crypto payment framework, partnering with Bybit, one of the world’s leading cryptocurrency exchanges. This partnership aims to bring seamless Web3 mobile payment capabilities to Bybit’s global user base of over 70 million users. AEON’s cutting-edge crypto payment solution is now natively embedded into Bybit’s platform, enabling QR-based crypto payments at 20 million merchants. This collaboration explores the use of AI and stablecoins to power smarter crypto transactions.

Hexagon’s Launch of AEON Humanoid

In a separate development, Hexagon has launched AEON, a humanoid robot designed for industrial applications. Leveraging its expertise in measurement technologies, AI, and autonomous systems, Hexagon introduces this advanced humanoid to accelerate next-generation autonomy. AEON combines best-in-class locomotion, sensor fusion, and AI-based spatial intelligence to address labor shortages and tackle various industrial use cases. Schaeffler and Pilatus will pilot the humanoid across a variety of use cases.

Market Context

While AEON Biopharma Inc. focuses on its core biopharmaceutical endeavors, the broader market has seen significant activity in the tech and crypto sectors. The expansion of the sales & service tax (SST) in Malaysia is expected to add an additional consumer cost of RM10 billion annually, representing 0.8% of Malaysia’s total domestic consumption. However, analysts from BIMB Securities believe this will not materially disrupt overall spending behavior, despite cautious sentiment ahead of subsidy rationalization.

This article provides a concise overview of AEON Biopharma Inc.’s current status and recent developments in related sectors, focusing on the company’s involvement in crypto payments and the launch of Hexagon’s AEON humanoid.